{"groups":[{"description":"Participants received 200 mg pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus best supportive care (BSC).","id":"FG000","title":"Pembrolizumab + BSC"},{"description":"Participants received placebo by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.","id":"FG001","title":"Placebo + BSC"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"269"},{"groupId":"FG001","numSubjects":"145"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"7"}],"type":"Sponsor Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"300"},{"groupId":"FG001","numSubjects":"153"}],"comment":"All randomized participants","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"299"},{"groupId":"FG001","numSubjects":"153"}],"comment":"First Course Pembrolizumab","type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Second Course Pembrolizumab","type":"Second Course"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"300"},{"groupId":"FG001","numSubjects":"153"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Male and female participants at least 18 years of age with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafenib or oxaliplatin-based chemotherapy with no curative option were enrolled in this study."}